Research Associate II/ III, Protein Biochemistry (Depending on Experience)
Apply
About Us
Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body's immune response and can destroy healthy tissue in certain patients.
Alexion discovered and developed Soliris® (eculizumab), a first-in-class terminal complement inhibitor approved in the United States, European Union, Canada and Australia as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion is working urgently to investigate Soliris and additional biopharmaceuticals as treatments for patients with other rare and severe diseases, including cancer.
Summary
Responsiblities:
- Works on the purification and functional characterization both of Alexion therapeutic targets and their associated reagents as well as therapeutic antibodies elicited against these targets.
- Carries out both conventional and affinity purification and applies a range of characterization techniques to ensure the structural and functional integrity of protein products.
- Detailed record keeping and organizational skills are required.
- Must be willing and able to multi-task on several such assignments within a multi-disciplinary, collaborative environment and demonstrate an enthusiasm for learning and applying new know-how.
Visa Sponsorship Not Available For This Position
Requirements
- BS/MS in biochemistry or related discipline with 2-5 years experience in protein purification and functional characterization.
- Expertise working with antibodies is desirable
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions. Employing more than 500 people worldwide, Alexion is engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic and kidney diseases, transplant, cancer, and autoimmune disorders. Soliris(R) (eculizumab) is Alexion's first marketed product for patients with paroxysmal noctural hemoglobinuria (PNH) a rare, debilitating and life-threatening blood disorder defined by the destruction of red blood cells, or hemolysis. Soliris is approved in the U.S. and Europe in 2007, and Canada and Australia in 2009. Alexion is evaluating other potential indications for Soliris as well as other formulations of eculizumab for additional clinical indications, and is pursuing development of other antibody product candidates in early stages of development.
Alexion offers a highly competitive package of base and incentive compensation, group healthcare coverage, tuition reimbursement, relocation assistance, and a 401(K) plan.
Alexion is an Equal Opportunity/Affirmative Action Employer.
Apply
